Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
- Conditions
- Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- David Peereboom
- Target Recruit Count
- 41
- Registration Number
- NCT04013672
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
- Conditions
- Lung Atypical Carcinoid TumorMetastatic Pancreatic Neuroendocrine TumorLung Typical Carcinoid Tumor
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03879694
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
- Conditions
- High Risk NeuroblastomaRefractory NeuroblastomaRecurrent Neuroblastoma
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 94
- Registration Number
- NCT03794349
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Kaiser Permanente Downey Medical Center, Downey, California, United States
Biomarker Assessments of Leukine During Treatment of Parkinson's Disease
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 7
- Registration Number
- NCT03790670
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- GanglioneuroblastomaHigh Risk Neuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationRadiation: External Beam Radiation Therapy
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
MIBG With Dinutuximab +/- Vorinostat
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Target Recruit Count
- 45
- Registration Number
- NCT03332667
- Locations
- 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Conditions
- GanglioneuroblastomaNeuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyRadiation: External Beam Radiation TherapyRadiation: Iobenguane I-123Radiation: Iobenguane I-131Procedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 724
- Registration Number
- NCT03126916
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
Sargramostim for Myeloid Dendritic Cell Deficiency
- Conditions
- Kidney DiseasesKidney Transplant
- Interventions
- Biological: Blood samples
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 4
- Registration Number
- NCT03063242
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 10
- Registration Number
- NCT03006146
- Locations
- 🇺🇸
University of California, Los Angeles, Los Altos, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Gliknik Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02873819
- Locations
- 🇭🇺
Bacs-Kiskun County Teaching Hospital, Kecskemét, Hungary
🇭🇺Medical Center of the University of Pecs, Pecs, Hungary
🇺🇦Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.